Contribute Try STAT+ Today

Following a three-year probe, Merck (MRK) reached a deal with Austrian regulators to end a “predatory” pricing strategy for a brain cancer treatment, the latest instance in which European authorities have scrutinized the pharmaceutical industry over anticompetitive practices.

The focus of the investigation was Temodal, which is used to treat such brain tumors as glioblastoma, the most frequent type of brain tumor in adults. Approximately 350 people develop this malady in Austria each year, but the Federal Competition Authority determined the company was making it difficult for lower-cost generic versions to reach the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.